$76.3 Million is the total value of Ally Bridge Group (NY) LLC's 18 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 126.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| VRNA | New | VERONA PHARMA PLCsponsored ads | $9,791,630 | – | 487,631 | +100.0% | 12.84% | – |
| XENE | New | XENON PHARMACEUTICALS INC | $9,554,534 | – | 266,961 | +100.0% | 12.52% | – |
| BLU | New | BELLUS HEALTH INC NEW | $8,149,154 | – | 1,131,827 | +100.0% | 10.68% | – |
| CYTK | New | CYTOKINETICS INC | $7,860,813 | – | 223,382 | +100.0% | 10.30% | – |
| MDGL | New | MADRIGAL PHARMACEUTICALS INC | $7,174,288 | – | 29,614 | +100.0% | 9.40% | – |
| ISEE | New | IVERIC BIO INC | $6,211,692 | – | 255,310 | +100.0% | 8.14% | – |
| MRUS | New | MERUS NV | $5,077,848 | – | 275,970 | +100.0% | 6.66% | – |
| MRSN | MERSANA THERAPEUTICS INC | $4,896,124 | -29.9% | 1,191,271 | 0.0% | 6.42% | -5.5% | |
| New | JASPER THERAPEUTICS INC | $4,556,190 | – | 2,517,232 | +100.0% | 5.97% | – | |
| SRPT | New | SAREPTA THERAPEUTICS INC | $2,870,999 | – | 20,830 | +100.0% | 3.76% | – |
| CTIC | New | CTI BIOPHARMA CORP | $2,310,000 | – | 550,000 | +100.0% | 3.03% | – |
| MDVL | MEDAVAIL HOLDINGS INC | $1,689,477 | -4.4% | 5,894,897 | 0.0% | 2.22% | +28.9% | |
| New | MDXHEALTH SAsponsored ads | $1,620,000 | – | 500,000 | +100.0% | 2.12% | – | |
| New | MOONLAKE IMMUNOTHERAPEUTICSclass a ord | $1,558,262 | – | 72,850 | +100.0% | 2.04% | – | |
| RAPID MICRO BIOSYSTEMS INC | $916,560 | +15.9% | 699,664 | 0.0% | 1.20% | +56.2% | ||
| EPIX | Sell | ESSA PHARMA INC | $702,652 | -65.6% | 236,583 | -70.8% | 0.92% | -53.7% |
| KNTE | New | KINNATE BIOPHARMA INC | $683,706 | – | 109,393 | +100.0% | 0.90% | – |
| Sell | SYROS PHARMACEUTICALS INC | $665,166 | -78.7% | 249,126 | -71.3% | 0.87% | -71.2% | |
| DNLI | Exit | DENALI THERAPEUTICS INC | $0 | – | -4,479 | -100.0% | -0.12% | – |
| Exit | SCIENCE 37 HOLDINGS INC | $0 | – | -384,397 | -100.0% | -0.16% | – | |
| NAUT | Exit | NAUTILUS BIOTECHNOLOGY INC | $0 | – | -159,232 | -100.0% | -0.28% | – |
| CRIS | Exit | CURIS INC | $0 | – | -827,397 | -100.0% | -0.44% | – |
| MOR | Exit | MORPHOSYS AGsponsored ads | $0 | – | -405,602 | -100.0% | -1.41% | – |
| PRAX | Exit | PRAXIS PRECISION MEDICINES I | $0 | – | -630,584 | -100.0% | -1.46% | – |
| RGEN | Exit | REPLIGEN CORP | $0 | – | -12,180 | -100.0% | -2.01% | – |
| MRTX | Exit | MIRATI THERAPEUTICS INC | $0 | – | -47,520 | -100.0% | -2.10% | – |
| RCKT | Exit | ROCKET PHARMACEUTICALS INC | $0 | – | -125,176 | -100.0% | -2.38% | – |
| Exit | BIOHAVEN LTD | $0 | – | -179,085 | -100.0% | -2.42% | – | |
| SELB | Exit | SELECTA BIOSCIENCES INC | $0 | – | -2,558,474 | -100.0% | -2.81% | – |
| NKTR | Exit | NEKTAR THERAPEUTICS | $0 | – | -1,334,661 | -100.0% | -2.93% | – |
| KPTI | Exit | KARYOPHARM THERAPEUTICS INC | $0 | – | -896,618 | -100.0% | -2.97% | – |
| ALKS | Exit | ALKERMES PLC | $0 | – | -142,002 | -100.0% | -3.61% | – |
| SANA | Exit | SANA BIOTECHNOLOGY INC | $0 | – | -1,015,273 | -100.0% | -3.90% | – |
| IRWD | Exit | IRONWOOD PHARMACEUTICALS INC | $0 | – | -326,428 | -100.0% | -3.94% | – |
| AMRN | Exit | AMARIN CORP PLCspons adr new | $0 | – | -3,730,859 | -100.0% | -4.39% | – |
| SAGE | Exit | SAGE THERAPEUTICS INC | $0 | – | -119,008 | -100.0% | -4.42% | – |
| AVIR | Exit | ATEA PHARMACEUTICALS INC | $0 | – | -962,694 | -100.0% | -4.50% | – |
| SGEN | Exit | SEAGEN INC | $0 | – | -37,639 | -100.0% | -4.71% | – |
| ALLK | Exit | ALLAKOS INC | $0 | – | -622,364 | -100.0% | -5.10% | – |
| GLPG | Exit | GALAPAGOS NVspon adr | $0 | – | -140,054 | -100.0% | -6.05% | – |
| ACAD | Exit | ACADIA PHARMACEUTICALS INC | $0 | – | -474,741 | -100.0% | -7.35% | – |
| Exit | AADI BIOSCIENCE INC | $0 | – | -632,997 | -100.0% | -7.90% | – | |
| RARE | Exit | ULTRAGENYX PHARMACEUTICAL IN | $0 | – | -185,261 | -100.0% | -8.35% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Fan Yu #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MEDAVAIL HOLDINGS INC | 11 | Q2 2023 | 8.9% |
| UNUM THERAPEUTICS INC | 8 | Q3 2022 | 7.3% |
| RAPID MICRO BIOSYSTEMS INC-A | 8 | Q2 2023 | 3.5% |
| FATE THERAPEUTICS INC | 7 | Q2 2022 | 5.8% |
| VIRIDIAN THERAPEUTICS INC | 7 | Q2 2023 | 6.8% |
| SYROS PHARMACEUTICALS INC | 7 | Q2 2022 | 4.9% |
| REPLIGEN CORP | 7 | Q4 2022 | 6.5% |
| NAUTILUS BIOTECHNOLOGY INC | 7 | Q4 2022 | 3.8% |
| ARVINAS INC | 6 | Q1 2022 | 7.5% |
| NUVATION BIO INC | 6 | Q2 2022 | 4.9% |
View Ally Bridge Group (NY) LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cogent Biosciences, Inc. | November 19, 2020 | 1,420,500 | 8.0% |
View Ally Bridge Group (NY) LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 4 | 2023-06-21 |
| 13F-HR | 2023-05-15 |
| 4 | 2023-03-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
View Ally Bridge Group (NY) LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.